All Updates

All Updates

icon
Filter
Partnerships
FogPharma and ARTBIO partner to co-develop novel therapies for multiple cancer types
AI Drug Discovery
May 14, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Yesterday
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Yesterday
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Yesterday
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Yesterday
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Yesterday
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Yesterday
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Yesterday
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Yesterday
AI Drug Discovery

AI Drug Discovery

May 14, 2024

FogPharma and ARTBIO partner to co-develop novel therapies for multiple cancer types

Partnerships

  • Precision Oncology and biotechnology company FogPharma and radiopharmaceutical biotechnology company ARTBIO have announced a partnership to develop cancer therapies. The financial terms of the agreement have not been disclosed; however, both parties have agreed to contribute equally across all stages from research to commercialization.

  • The collaboration will leverage FogPharma’s Helicon platform's peptide capabilities and ARTBIO’s AlphaDirect platform for radioligand therapies to jointly develop Helicon-enabled ARTs (HEARTs) for multiple cancers. 

  • Massachusetts-based FogPharma is discovering and developing Helicon Therapeutics, a new class of precision medicines that can reach difficult targets. These peptides can enter cells and regulate interactions between proteins and DNA. By leveraging Helicon Therapeutics' potential, the company seeks to target intracellular mechanisms known to play pivotal roles in diseases.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.